Table 3 Comparisons of categorical data between migraine cases according to MRI findings
From: Migraine in patients with rheumatoid arthritis and its relation to disease activity
Qualitative data | Normal brain MRI | Abnormal brain MRI | χ2 | P value |
|---|---|---|---|---|
N (%) | 28 (45.2%) | 34 (54.8%) | ||
Sex | FET | 0.450 | ||
Male | 5 (17.9%) | 3 (8.8%) | ||
Female | 23 (82.1%) | 31 (91.2%) | ||
Current smoking | 3 (10.7%) | 6 (17.6%) | FET | 0.494 |
Positive RF | 20 (71.4%) | 23 (67.6%) | 0.103 | 0.748 |
Positive anti-CCP | 23 (82.1%) | 31 (91.2%) | FET | 0.450 |
Rheumatoid Disease Activity | FET | 0.393 | ||
Remission (DAS28 < 2.6) | 3 (10.7%) | 3 (8.8%) | ||
Low (DAS28 ≥ 2.6 to ≤ 3.2) | 10 (35.7%) | 7 (20.6%) | ||
Moderate (DAS28 > 3.2 to ≤ 5.1) | 15 (53.6%) | 22 (64.7%) | ||
High (DAS28 > 5.1) | 0 (0%) | 2 (5.9%) | ||
Functional losses (MHAQ) | 0.754 | 0.686 | ||
Mild (MHAQ < 1.3) | 11 (39.3%) | 10 (29.4%) | ||
Moderate (MHAQ 1.3 to 1.8) | 10 (35.7%) | 13 (38.2%) | ||
Severe (MHAQ > 1.8) | 7 (25%) | 11 (32.4%) | ||
Fibromyalgia | 6 (21.4%) | 8 (23.5%) | 0.039 | 0.844 |
Sjogren's syndrome | 3 (10.7%) | 4 (11.8%) | FET | 1.000 |
NSAIDs use | 0 (0%) | 5 (14.7%) | FET | 0.058 |
Corticosteroid use | 6 (21.4%) | 3 (8.8%) | FET | 0.277 |
Methotrexate use | 18 (64.3%) | 20 (58.8%) | 0.193 | 0.660 |
Sulfasalazine use | 2 (7.1%) | 3 (8.8%) | FET | 1.000 |
Leflunomide use | 1 (3.6%) | 2 (5.9%) | FET | 1.000 |
Anti-TNF-α use | 0 (0%) | 3 (8.8%) | FET | 0.245 |
Hydroxychloroquine use | 13 (46.4%) | 16 (47.1%) | 0.002 | 0.961 |
Migraine type | FET | 1.000 | ||
Episodic | 25 (89.3%) | 30 (88.2%) | ||
Chronic | 3 (10.7%) | 4 (11.8%) | ||
Migraine with aura | 5 (17.9%) | 14 (41.2%) | 3.929 | 0.047 |
Numerical Rating Scale | FET | 0.445 | ||
Mild | 7 (25%) | 4 (11.8%) | ||
Moderate | 9 (32.1%) | 12 (35.3%) | ||
Severe | 12 (42.9%) | 18 (52.9%) |